Silence Therapeutics promotes Jorg Kaufmann
pharmafile | May 21, 2010 | Appointment | Research and Development | Silence Therapeutics, appointment, research and development, rnai
Jorg Kaufmann has been made vice president of research at UK biotech company Silence Therapeutics.
He previously served as senior director of technologies, and in his new role he will play a key role overseeing Silence’s range of RNA interference (RNAi) research activities.
Silence’s chief scientific officer Klaus Giese said: “In his time at Silence Dr. Kaufmann has proven himself a valued member of our research team, playing a significant role in advancing a number of our novel RNAi technologies including proprietary RNAi delivery platforms and innovative approaches siRNA structural modification.
“The ongoing successes achieved by our team of scientists in Berlin combined with the consolidation of all research activities to our Berlin location, has created a need to continue to strengthen our research organisation.”
Jorg has more than 13 years of biotechnology industry experience in both the US and Europe. Since joining Silence in 2000, he has served as both senior and associate director, technologies, and prior to joining Silence was a senior scientist at Chiron.
He will continue to be based at Silence’s Berlin research centre, where the company recently announced it is consolidating all research activities related to its novel RNAi therapeutic platforms.
Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …






